Biotechnology

#Accelerated Bio #Biomanufacturing #Biotechnology #Cell engineering #Mekonos #Stem cells

New cell engineering partnership to accelerate biopharma innovation 

Mekonos, a company working towards cell engineering on a chip, has entered into a partnership agreement with Accelerated Bio to codevelop a new manufacturing cell line based on Accelerated Bio’s human Trophoblast Stem Cells (hTSCs) and Gene Engineered Multi-Sites (GEMS) technology.  Dr Anil Narasimha, Co-founder and Chief… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Biotechnology #Broken String Biosciences #DNA #Francis Crick Institute #Genomics

UK industry collaboration to advance ALS research 

Broken String Biosciences has entered a research collaboration with the Francis Crick Institute, focused on leveraging technology to investigate the impact of genomic instability in the development of amyotrophic lateral sclerosis (ALS).  The aim to achieve this is through the development of novel applications for Broken String’s… Read More

#News

HIV cell
#Biotechnology #Clinical trials #HIV #Immunology / Virology & Vaccines #Naobios #Sumagen

Naobios and Sumagen partner to develop HIV vaccine 

Naobios has signed a partnership agreement with Sumagen, a Korean-Canadian biotechnology company developing an HIV-1 vaccine candidate, to manage the manufacturing process during its Phase II clinical trials.  At the end of 2022, the World Health Organization (WHO) reported that approximately 39 million people were living with HIV. Developing an… Read More

#Business & Investment #News

Blood cells
#Biotechnology #Collaboration #Funding #Haematology #Hemostatics

Validating a revolutionary therapy against lethal haemorrhage 

A public-private consortium formed by the biotech Hemostatics, based at the Barcelona Science Park, the Clínica Universidad de Navarra (CUN) and the Institute of Chemical Research of Catalonia (ICIQ), has received €2.5 million from the Spanish Research Agency (AEI), under the call for grants for Public-Private Collaboration Projects, to… Read More

#News

#3D chemistry #AI #Artificial intelligence (AI) #Biologics #Biotechnology #Cell and gene therapy #Contract development and manufacturing organisations #Covid-19 #Gene expression #Gene mutation #Interview #mRNA #Next generation sequencing #Oncology #PharmEnable #RNA sequencing #Single-cell RNA sequencing #Vaccines

Podcast: What trends will speed up the journey from clinic to bedside?

This is the latest episode of the free DDW narrated podcast, titled “What trends will speed up the journey from clinic to bedside?” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Sitting down with… PharmEnable, Is single-cell… Read More

#News

Marine Diatom colony
#Biotechnology #DNA #Drug discovery #Genetics / genomics #Microbiology

World’s largest catalogue of ocean DNA could boost drug discovery

The world’s most comprehensive database for understanding microbial distribution and function in the ocean has been released, opening up new opportunities for drug discovery. Scientists at the King Abdullah University of Science and Technology (KAUST) in Thuwal, Saudi Arabia used the KAUST Metagenomic Analysis Platform (KMAP)… Read More

#News

#Biotechnology #Concussion #Neurology #Neuroscience #Oxeia Biopharmaceuticals #University of Kansas Medical Center (KUMC)

“Game changing” concussion drug study shows positive early results  

Oxeia Biopharmaceuticals, a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury, has announced “game-changing” results of a Phase IIa pilot study of OXE103 at the University of Kansas Medical Center (KUMC).   The study results suggest a potentially… Read More

#News

Cancer tumour
#Biotechnology #Cancer research #iOnctura #Tumours

New research highlights potential of combination cancer treatment 

iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumour survival pathways, has published new research data in the peer-reviewed journal Cancer Research, that supports a strategy of combining autotaxin inhibitor IOA-289 with TGF-β pathway inhibitor IOA-359.   Resistance to TGF‐β… Read More

#Cancer Research #News

#Biotechnology #Funding #Immunology / Virology & Vaccines #MinervaX

Funding to advance maternal vaccine against streptococcus 

MinervaX, a Danish biotechnology company developing a novel, prophylactic vaccine against Group B streptococcus (GBS), has announced the completion of €54 million upsized financing.   GBS is a leading cause of life-threatening infections in newborns as well as adverse pregnancy outcomes such as preterm delivery and stillbirths. Read More

#News

#AI / data analytics / healthtech / informatics #Biotechnology #Drug development #Drug discovery #Technology

This week in drug discovery (11-15 September)  

News round-up for 11-15 September by DDW Digital Content Editor Diana Spencer. Spanning artificial intelligence, theranostics, radiopharmaceuticals, quantum simulation and small regulatory RNA, the top stories this week all cover cutting-edge technologies and techniques making a huge impact on modern drug discovery and development. Read More

#News

Conference speaker
#AusBiotech #Australia #Biotechnology #Events #Immunology / Virology & Vaccines

Ian Frazer revealed as keynote speaker for AusBiotech 2023

Emeritus Professor Ian Frazer, University of Queensland and Director of Microba, has been announced as the Millis Oration keynote speaker for AusBiotech 2023. The title of his presentation will be ‘Navigating the future: Predictions and potential of Australian biotechnology’. He will share his assessment… Read More

#News

#Acquisition #Biopharma #Biotechnology #CDMO #Cell and gene therapy #Cold chain #Drug development #GSK #Pfizer #Regulatory #Supply chain

New podcast: A business case for drug discovery

This is the latest episode of the free DDW narrated podcast, “A business case for drug discovery”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “A deal in the making”, “Why project management… Read More

#News

Gram positive cocci in chain bacteria, Streptococcus, a type of bacteria
#Biotechnology #Clinical trials #Group B Streptococcus #Immunology / Virology & Vaccines #MinervaX #Streptococcus

Full enrolment for Phase I clinical trial of Group B streptococcus  

MinervaX, a Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), has completed enrolment and initial dosing in its Phase I clinical vaccine trial in older adults. The trial is taking place at CEVAC (Centre for Vaccinology), Ghent University, Belgium.  GBS is most… Read More

#News

Blood cells
#Autoimmune disease #Biotechnology #Haemodialysis #Invizius

‘Angry Blood’ haemodialysis study recruits its 300th patient 

Invizius, a biotechnology company developing second generation therapies for a range of complement-driven autoimmune and inflammatory disorders, has recruited its 300th patient to the ‘Angry Blood’ study.   This is a significant milestone in its novel kinetic study to identify patients with elevated complement responses… Read More

#News

Biotechnology
#Biotechnology #Comment #Events #Genomics #LSX World Congress

Comment: LSX World Congress 2023 

The LSX World Congress 2023 took place at the Business Design Centre in London, UK in May 2023. DDW’s Megan Thomas comments on the event.   New approaches to partnering   In this event in the Biotech track, Clive Cookson, Science Editor at the Financial Times, interviewed John McDonald, Corporate Vice President,… Read More

#Exclusive Content #Opinion